Form 4: Clene Inc. Director Arjun Desai Acquires Stock Options
SEC Form 4
Director Arjun Desai acquired 3,319 stock options in Clene Inc. on February 27, 2025, according to a Form 4 filing.
Summary
- On February 27, 2025, Arjun Desai, a director of Clene Inc., acquired 3,319 stock options.
- The options were granted under the Clene Inc. Amended 2020 Stock Plan.
- The exercise price for the options is $4.42 per share.
- The options vest immediately upon grant and expire on February 26, 2035.
- The reporting person now directly owns 3,319 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, indicating a neutral sentiment.
Positives
- The immediate vesting of the options could incentivize the director to work towards the company's success.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and directors.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
- Companies like BioNTech and Moderna also use stock options as part of their compensation strategy.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of transaction: Arjun Desai acquired stock options. |
| 02/28/2025 | Date of report: Form 4 filing date. |
| 02/26/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.